Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Pliant Therapeutics (PLRX) Preferred Shares Issued (2020)

Pliant Therapeutics has reported Preferred Shares Issued over the past 1 years, most recently at -$19000.0 for Q2 2020.

Quarterly Preferred Shares Issued changed N/A to -$19000.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was -$19000.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $52.0 million for FY2020, 8.49% up from the prior year.
Preferred Shares Issued was -$19000.0 for Q2 2020 at Pliant Therapeutics, down from $52.0 million in the prior quarter.
Over five years, Preferred Shares Issued peaked at $52.0 million in Q1 2020 and troughed at -$19000.0 in Q2 2020.